Lilly (Eli)

Direction: Raised

Revenue: “com (317) 617-0983 (Investors) Lilly reports third-quarter 2025 financial results, highlights R D pipeline momentum and raises 2025 guidance Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound .”

Revenue: “Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70.”

Revenue: “7 2025 Financial Guidance The company has increased full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.”

EPS: “Based on these changes, EPS guidance has been increased to be in the range of $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis.”

Revenue: “8 The following table summarizes the company's updated 2025 financial guidance Prior Updated (1) (2) (3) Revenue $60.0 to $62.0 billion $63.0 to $63.5 billion Performance Margin (4) (reported) 42.0% to 43.5% 43.5% to 44.5% (non-GAAP) 43.0% to 44.5% 45.0% to 46.0% Other Income (Expense) (reported) ($750) to ($650) million ($700) to ($600) million Other Income (Expense) (non-GAAP) ($700) to ($600) million Unchanged Tax Rate (reported) Approx.”

EPS: “17% Unchanged Earnings per Share (reported) $20.85 to $22.10 $21.80 to $22.50 Earnings per Share (non-GAAP) $21.75 to $23.00 $23.00 to $23.70 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above.”

Revenue — Raised (“raises”)
“com (317) 617-0983 (Investors) Lilly reports third-quarter 2025 financial results, highlights R D pipeline momentum and raises 2025 guidance Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound .”

Revenue — Raised (“Increased”)
“Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70.”

Revenue — Raised (“increased”)
“7 2025 Financial Guidance The company has increased full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.”

Revenue — Raised (“increase”)
“Both ratios reflect the increase in revenue guidance.”

EPS — Raised (“increased”)
“Based on these changes, EPS guidance has been increased to be in the range of $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis.”

Revenue — Reiterated (“Unchanged”)
“8 The following table summarizes the company's updated 2025 financial guidance Prior Updated (1) (2) (3) Revenue $60.0 to $62.0 billion $63.0 to $63.5 billion Performance Margin (4) (reported) 42.0% to 43.5% 43.5% to 44.5% (non-GAAP) 43.0% to 44.5% 45.0% to 46.0% Other Income (Expense) (reported) ($750) to ($650) million ($700) to ($600) million Other Income (Expense) (non-GAAP) ($700) to ($600) million Unchanged Tax Rate (reported) Approx.”

EPS — Reiterated (“Unchanged”)
“17% Unchanged Earnings per Share (reported) $20.85 to $22.10 $21.80 to $22.50 Earnings per Share (non-GAAP) $21.75 to $23.00 $23.00 to $23.70 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above.”

Classified from the release's primary full-year outlook statement.